Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC

Published Date: 13 Sep 2024

Two-trial analysis shows about a 40% decreased risk of disease recurrence or death

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Compared to previous estimates, a greater number of patients participate in cancer treatment trials.

2.

Zebrafish models offer fast, effective guidance for personalized therapies for kids with high-risk cancer

3.

Let's Talk Breast Density; Cancer, Movies, and Music; Treatment-Induced Aging?

4.

Researchers use AI to monitor side effects of chemotherapy and support families dealing with pediatric cancer.

5.

The diamonds that could find cancer


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot